AbbVie’s immunology portfolio, anchored by Rinvoq and Skyrizi, continues to drive revenue growth as the company transitions beyond Humira’s patent cliff. For Q3 2026, global Rinvoq net revenues reached $2.706 billion, reflecting a 23.9% year-over-year increase on a reported basis and a 24.3% operational gain, outpacing the broader immunology segment’s 16.3% rise. This performance stems from expanded label indications across inflammatory conditions, sustained market-share gains, and robust demand in both established and newer therapeutic areas. The company simultaneously lifted full-year adjusted EPS guidance to $13.95–$13.99 after beating consensus estimates, supported by the recent Apogee Therapeutics acquisition that bolsters the late-stage pipeline. Traders are therefore focused on whether these momentum factors push Rinvoq above the specific revenue threshold embedded in the market contract.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour1H6H1D7D30DALL
View resolved

Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes